The OHSU Physician Advice and Referral Service makes physician referrals as easy as possible. Patients require a referral placed by their PCP or referring provider. Medical records will be required as part of the referral process. Here you’ll find forms, an FAQ page, step-by-step instructions and a guide to our process. Please visit the OHSU Referral Service page for further information.

1. Refer a patient for diabetes or prediabetes education
2. Complete the OHSU Referral Form and fax to 503-346-6854
   • Select Diabetes Education (under Endocrinology) on the left side.
   • Specify the type of education visit. Choose one of the following and enter selection under specific medical issue to address at the visit:
     • ​​​​​​​Diabetes
       • ​​​​​​​Type 2 diabetes program *preferred for newly diagnosed type 2 diabetes
       • Individual diabetes education
       • Nutrition
     • Prediabetes 
       • One-time prediabetes class
       • National Diabetes Prevention Program
       • Nutrition
   • Attach Labs and medications (chart notes optional).

​​​​​​​

​​​​​​​​​​​​​​

​​​​​​​

Please call: 503-494-4704 or have your patient complete our Diabetes Research Online Form

The Harold Schnitzer Diabetes Health Center promotes and supports a vibrant and exciting research program integrated into the clinical care. Below are our ongoing research studies.

Open for Recruitment

Type 1 Diabetes

Sugar N Salt – Funded by Breakthrough T1D, formerly JDRF

• Protocol Title: Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease (The SUGARNSALT Trial)
• Primary Objective: To determine the effectiveness of sotagliflozin (SOTA) in slowing eGFR decline in persons with type 1 diabetes (T1D) and moderate to severe diabetic kidney disease (DKD).
• Secondary Objectives: To institute and evaluate the feasibility of an advanced diabetic ketoacidosis (DKA) mitigation protocols for the safe use of sotagliflozin in persons with T1D and moderate to advanced DKD, including prevention, monitoring, and treatment of DKA. To evaluate the effectiveness of SOTA on biomarkers of early heart failure stages in people with T1D
• This trial is very important because SOTA has been shown to have important cardio-renal benefits in people with type 2 diabetes, including prevention of DKD and HF progression, and if successful may lead to its approval for DKD progression prevention people with T1D
• Phase: 3
• Study Population: This study will enroll adults with CKD and T1D.
  • ³18 years of age
  • T1D continuously treated with insulin
  • HbA1c at screening < 10%
  • Clinical diagnosis of CKD
    • eGFR between 20 and 60 mL/min/1.73m² at screening
    • UACR ³ 200 mg/g at screening
  • Receiving standard of care RASB treatment
• Duration: About 3 years and 4 months

NIDDK Foot Consortium – funded by NIDDK

• Protocol Title: The Diabetic Foot Consortium Master Platform Study Protocol: A New Tool to Address Diabetic Foot Ulcers (DFUs)
• Summary: This is an innovative platform master protocol that enrolls all people with DFUs as seen at the point of care testing multiple biomarkers concomitantly
•  Primary Objectives:
  • To identify sensitive and specific biomarkers that can accurately predict healing vs non healing in people with DFUs in addition to the standards of care.
  • To assess the proportion of participants who develop infections among those with no infection during the course of DFU
  • the proportion of participants who undergo any amputation involving the index (enrolled) foot ulcer
  • assessment of how the standard of care is provided specifically for offloading, vascular assessment, and performance of debridement
• Secondary Objective: Time to healing, defined as the time (in weeks) from baseline to complete healing. Change from baseline to later of Week 52 or Confirmation Visit in: SF-12 physical domain score, SF-12 mental domain score, DFS-SF subscale scores (leisure, physical health, dependence/daily life, negative emotions, worried about ulcers/feet, bother by ulcer care), PROMIS Sleep disturbance.
• Study Population:
  • ³18 years of age
  • Clinically diagnosed with diabetes
  • Open foot ulcer, defined as an open wound from malleolus down

Type 2 Diabetes

TINSAL-FISH – Funded by NIDDK as R01

• Protocol Title: Effect of Fish Oil ± Salsalate on the Omega-3 Index and the Circulating Lipodome of Omega-3 Polyunsaturated Fatty Acid Metabolites in Patients with Type 2 Diabetes (T2D) and Diabetic Peripheral Neuropathy (DPN) (TINSAL-FISH)

Summary: The OHSU Harold Schnitzer Diabetes Center (PI: Dr. Rodica Busui, MD PhD) is part of a multicenter trial funded by the National Institute of Health to identify new therapies that could reverse diabetic neuropathy, a very common and challenging complication of diabetes that leads to nerve damage and loss. The trial is evaluating whether fish oil, alone and in combination with salsalate, an old drug approved to treat arthritis may be effective to treat diabetic peripheral neuropathy, and identify new targets that could be tested in a future trial. This study is being conducted at the University of Iowa, at the University of Michigan, and Oregon Health and Sciences University (OHSU).

• Primary Objective: To determine the most effective dosing combination that will raise the omega-3 index (defined as the sum of EPA and DHA, see above), as a percentage of total fatty acids in red blood cells) to therapeutic levels, healthy range 8-12%, leading to a maximum increase in circulating levels of resolvins.
• Secondary Objective: To evaluate the safety and efficacy of salsalate and fish oil combination to be tested in a subsequent trial as a disease modifying treatment for DPN.
• Phase: 2
• Study Population: This study will enroll adults with T2D and diabetic polyneuropathy.
  • ³18 years of age
  • T2D
  • HbA1c < 9.5%
  • Presence of diabetic polyneuropathy
  • Agree to not use NSAIDs or NSAID-like medications
• Duration: About 6 months

NIDDK Foot Consortium – funded by NIDDK

• Protocol Title: The Diabetic Foot Consortium Master Platform Study Protocol: A New Tool to Address Diabetic Foot Ulcers (DFUs)
• Summary: This is an innovative platform master protocol that enrolls all people with DFUs as seen at the point of care testing multiple biomarkers concomitantly
•  Primary Objectives:
  • To identify sensitive and specific biomarkers that can accurately predict healing vs non healing in people with DFUs in addition to the standards of care.
  • To assess the proportion of participants who develop infections among those with no infection during the course of DFU
  • the proportion of participants who undergo any amputation involving the index (enrolled) foot ulcer
  • assessment of how the standard of care is provided specifically for offloading, vascular assessment, and performance of debridement
• Secondary Objective: Time to healing, defined as the time (in weeks) from baseline to complete healing. Change from baseline to later of Week 52 or Confirmation Visit in: SF-12 physical domain score, SF-12 mental domain score, DFS-SF subscale scores (leisure, physical health, dependence/daily life, negative emotions, worried about ulcers/feet, bother by ulcer care), PROMIS Sleep disturbance.
• Study Population:
  • ³18 years of age
  • Clinically diagnosed with diabetes
  • Open foot ulcer, defined as an open wound from malleolus down

​​​​​​​Ongoing – Recruitment Closed

Bayer FINE-ONE – funded by Bayer

• Protocol Title: A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes (FINE-ONE)
• Primary Objective: To demonstrate that finerenone in addition to standard of care (SoC) is superior to placebo in reducing urine albumin excretion rate over 6 months in participants with chronic kidney disease (CKD) and type 1 diabetes (T1D)
• This trial is important because finerenone has been shown to have important cardio-renal benefits in people with type 2 diabetes, and if successful may lead to its approval for people with T1D
• Secondary Objective: To assess the safety of finerenone in addition to SoC compared to placebo
• Phase: 3
• Study Population: This study will enroll adults with CKD and T1D.
  • ³18 years of age
  • T1D continuously treated with insulin
  • HbA1c at screening < 10%
  • Clinical diagnosis of CKD
    • eGFR ³25 and < 90 mL/min/1.73m² at screening
    • UACR ³ 200 mg/g - <5000 mg/g at screening
  • On a stable (without any changes in dosage for at least 4 weeks prior to screening) ACEI or ARB treatment
• Duration: About 7.5 months

November 2020

"Structural Inequities and Diabetes: Challenges and Solutions"

Speaker:
Monica Peek, M.D., M.P.H., M.S., FACP

Watch the recorded lecture.